About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings ... and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, ...

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that ...

Biotechnology, a field traditionally focused on harnessing biological processes for agricultural, medical, and environmental ...

"Mr. Deming's extensive experience in in the biopharma sector, both through his investment banking career and service on a number of corporate boards provides a valuable resource to Phio as we pursue ...

I will start by saying that biotechnology is a game Changer, it has revolutionised various fields, including medicare, agricultural business, industrial engineering and environmental science, ...

USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...

Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch ...

The concerns have grown amidst sweeping layoffs at federal health agencies, a lag in research funding and efforts by the NIH ...

The gross proceeds from the offering are expected to be $2,715,000, prior to offering expenses payable by the Company. The Company intends to use the net proceeds received from the private placement ...

According to leading experts, the following topics must now feature at the very top of the political agenda: the transition ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $1.05 million, before ...